National surveillance of nosocomial blood stream infection due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE program

Diagnostic Microbiology and Infectious Disease

Volumn 31, Issue 1, 1998, Pages 327-332

  Pfaller, M A ^a   Jones, R N ^a   Messer, S A ^a   Edmond, M B ^b   Wenzel, R P ^b  

^a UNIVERSITY OF IOWA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE;

ARTICLE; BLOOD; CANDIDA ALBICANS; DRUG SENSITIVITY; FUNGUS IDENTIFICATION; GEOGRAPHIC DISTRIBUTION; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; FLUCONAZOLE; FUNGEMIA; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS;

EID: 0031899916     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)00240-X     Document Type: Article

References (30)

1. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis. 24:1997;1122-1128.
2. Archibald L, Phillips L, Monnet D, McGowan JE Jr, Tenover F, Gaynes R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States Increasing importance of the intensive care unit . Clin Infect Dis. 24:1997;211-215.
3. Arevalo MP, Arias A, Andrea A, Rodriguez C, Sierra A. Fluconazole, itraconazole, and ketoconazole in vitro activity against Candida spp. J Chemother. 6:1994;226-229.
4. Banerjee SN, Emori TG, Culver DH, Gaynes RP, Jarvis WR, Horan T, Edwards JR, Tolson JS, Henderson T, Martone WJ. Secular trends in nosocomial primary blood stream infections in the United States, 1980-1989. Am J Med. 91:(suppl 3B):1991;86S-89S.
5. Beck-Sague CM, Jarvis WR. National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis. 167:1993;1247-1251.
6. Dermoumi H. In vitro susceptibility of fungal isolates of clinically important specimens to itraconazole, fluconazole and amphotericin B. Chemotherapy. 40:1994;92-98.
7. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev. 6:1993;428-442.
8. Fisher-Hoch SP, Hutwagner L. Opportunistic candidiasis an epidemic of the 1980s . Clin Infect Dis. 21:1995;897-904.
9. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev. 9:1996;499-511.
10. Ghannoum MA, Rex JH, Galgiani JH. Susceptibility testing of fungi current status of the correlation of in vitro data with clinical outcome . J Clin Microbiol. 34:1996;489-495.
11. Reference method for broth dilution antifungal susceptibility testing of yeasts approved standard M27-A . 1997;NCCLS, Wayne, PA.
12. Nguyen MH, Peacock JE, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, Wagener MM, Rinaldi MG, Yu VL. The changing face of candidemia emergence of non-Candida albicans species and antifungal resistance . Am J Med. 100:1996;617-623.
13. Pfaller MA. Nosocomial candidiasis emerging species, reservoirs, and modes of transmission . Clin Infect Dis. 22:(suppl 2):1996;S89-S94.
14. Pfaller MA, Rhine-Chalberg J, Redding SW, Smith J, Farinacci G, Fothergill AW, Rinaldi MG. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol. 32:1994;59-64.
15. Pfaller MA, Barry AL. In vitro susceptibilities of clinical yeast isolates to three antifungal agents determined by the microdilution method. Mycopathologia. 130:1995;3-9.
16. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP (1997b) National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 29:30:121-129.
17. Pfaller MA, Lockhart SR, Pujol C, Messer SA, Edmond MB, Jones RN, Wenzel RP, Soll DR (1998) Hospital specificity, regional specificity, and fluconazole-resistance of Candida albicans isolates obtained from blood stream infections throughout the continental United States. J Clin Microbiol (submitted).
18. Pittet D, Li N, Woolson RF, Wenzel RP. Microbiological factors influencing the outcome of nosocomial blood stream infections a 6-year validated, population-based model . Clin Infect Dis. 24:1997;1068-1078.
19. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother. 38:1994;1422-1424.
20. Reimer LG, Wilson ML, Weinstein MP. Update on detection of bacteremia and fungemia. Clin Microbiol Rev. 10:1997;444-465.
21. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD. Antifungal susceptibility testing of isolates from a randomized multicenter trial of fluconazole versus amphotericin B as treatment of non-neutropenic patients with candidemia. Antimicrob Agents Chemother. 39:1995;40-44.
22. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 39:1995;1-8.
23. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Rinaldi MG, Walsh TJ, Barry AI. Development of interpretive breakpoints for antifungal susceptibility testing conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections . Clin Infect Dis. 24:1997;235-247.
24. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med. 91:(suppl 3B):1991;72S-75S.
25. Swartz MN. Hospital-acquired infections diseases with increasingly limited therapies . Proc Natl Acad Sci USA. 91:1994;2420-2427.
26. Voss A, Kluytmans JJAW, Koeleman JGM, Spanjaard L, Vandenbroucke-Grauls CMJE, Verbrugh HA, Vos MC, Weersink AYL, Hoogkamp-Korstanje JAA, Meis JFGM. Occurrence of yeast blood stream infections between 1987 and 1995 in five Dutch university hospitals. Eur J Clin Microbiol Infect Dis. 15:1996;909-912.
27. Wardle HM, Law D, Moore CB, Mason C, Denning DW. In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida spp. Antimicrob Agents Chemother. 39:1995;868-871.
28. Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, Reller LB. The clinical significance of positive blood cultures in the 1990s a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults . Clin Infect Dis. 24:1997;584-602.
29. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia The attributable mortality and excess length of stay . Arch Intern Med. 148:1988;2642-2645.
30. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis. 20:1995;115-125.